Bonus Biogroup Announces Completion Of Patient Recruitment For Its Clinical Trial In Human Maxillofacial Bone Deficiency

HAIFA, Israel--(BUSINESS WIRE)--Bonus BioGroup announced today (Thursday), that it was notified by the investigator at the medical center of the completion of recruitment of 20 patients - the maximal number approved for this clinical trial. The latter aims to treat human maxillofacial bone deficiencies by viable autologous human bone transplants.

In April 2014, Bonus BioGroup launched a clinical trial for the repair of maxillofacial bone deficiency, including upper and lower jawbone cavitation, by transplantation of live human bone grafts. These grafts, also termed transplants, comprise of cells originating from patients' own (autologous) fat tissue. The endpoint of the clinical trial is to evaluate the transplants’ safety and efficacy.

The transplants are manufactured in Bonus BioGroup’s production facility at Matam Advanced Technology Park, Haifa, Israel. The facilities and clinical trial activities, starting from the development stage, through production, quality control and product supply, are GMP as well as ISO-9001 certified.

The company estimates that the manufactured transplants which originate from and return to the same patients, will be fully integrated and immunologically tolerated. Upon introduction of Bonus BioGroup’s transplants into patients’ bodies, the biological identity of the transplants is expected to be recognized by the patients’ immune system. Thus the common immunological response and rejection typical of foreign donor tissue transplantation are anticipated to be prevented.

Bonus BioGroup produces personalized viable human bone transplants based on cells extracted from patients’ own fat tissue. The company's unique technology combines disciplines such as biology, tissue engineering, material engineering and tailored medicine.